The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial
- PMID: 36235736
- PMCID: PMC9570726
- DOI: 10.3390/nu14194084
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial
Abstract
Palmitoylethanolamide (PEA) is marketed as a "dietary food for special medical purposes". Its broad-spectrum analgesic, anti-inflammatory, and neuroprotective effects make PEA an interesting substance in pain management. However, the underlying analgetic mechanisms have not yet been investigated in humans. The aim of our study is to provide a deeper understanding of the involved mechanisms, which is essential for differentiating therapeutic approaches and the establishment of mechanism-based therapeutic approaches. In this randomized, placebo-controlled, double-blinded crossover trial, 14 healthy volunteers were included. PEA (3 × 400 mg per day) or placebo were taken for 4 weeks. Our study investigated the mode of action of PEA using an established pain model, "Repetitive phasic heat application", which is well-suited to investigate analgesic and anti-hyperalgesic effects in healthy volunteers. Parameters for peripheral and central sensitization as well as for pain modulation were assessed. Repetitive heat pain was significantly decreased, and the cold pain tolerance was significantly prolonged after the PEA treatment. The pressure pain tolerance and the conditioned pain modulation were increased after the PEA treatment. The wind-up ratio and the average distance of allodynia were significantly decreased after the PEA treatment. The heat pain tolerance was significantly higher after the PEA treatment. The present study has demonstrated that PEA has clinically relevant analgesic properties, acting on both peripheral and central mechanisms as well as in pain modulation.
Keywords: allodynia; central sensitization; conditioned pain modulation; hyperalgesia; pain; palmitoylethanolamide; peripheral sensitization; wind-up.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.J Neuroinflammation. 2014 Aug 28;11:136. doi: 10.1186/s12974-014-0136-0. J Neuroinflammation. 2014. PMID: 25164769 Free PMC article.
-
The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.Pain. 2008 Oct 31;139(3):541-550. doi: 10.1016/j.pain.2008.06.003. Epub 2008 Jul 3. Pain. 2008. PMID: 18602217
-
Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial.Pain. 2016 Sep;157(9):2097-2103. doi: 10.1097/j.pain.0000000000000623. Pain. 2016. PMID: 27227691 Clinical Trial.
-
ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain.Int J Mol Sci. 2020 Jul 27;21(15):5330. doi: 10.3390/ijms21155330. Int J Mol Sci. 2020. PMID: 32727084 Free PMC article. Review.
-
Palmitoylethanolamide in CNS health and disease.Pharmacol Res. 2014 Aug;86:32-41. doi: 10.1016/j.phrs.2014.05.006. Epub 2014 May 17. Pharmacol Res. 2014. PMID: 24844438 Review.
Cited by
-
Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants-A Double-Blind Randomised Controlled Study.Pharmaceuticals (Basel). 2024 Jan 23;17(2):145. doi: 10.3390/ph17020145. Pharmaceuticals (Basel). 2024. PMID: 38399360 Free PMC article.
-
The effect of photobiomodulation on histamine and Mucuna pruriens-induced pruritus, hyperknesis and alloknesis in healthy volunteers: A double-blind, randomized, sham-controlled study.PLoS One. 2024 Jul 18;19(7):e0307034. doi: 10.1371/journal.pone.0307034. eCollection 2024. PLoS One. 2024. PMID: 39024251 Free PMC article. Clinical Trial.
-
Neuro-Nutritional Approach to Neuropathic Pain Management: A Critical Review.Nutrients. 2025 Apr 29;17(9):1502. doi: 10.3390/nu17091502. Nutrients. 2025. PMID: 40362812 Free PMC article. Review.
-
A Fixed Combination of Palmitoylethanolamide and Melatonin (PEATONIDE) for the Management of Pain, Sleep, and Disability in Patients with Fibromyalgia: A Pilot Study.Nutrients. 2024 Aug 21;16(16):2785. doi: 10.3390/nu16162785. Nutrients. 2024. PMID: 39203921 Free PMC article.
-
Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidome.Front Neurosci. 2024 Nov 27;18:1506352. doi: 10.3389/fnins.2024.1506352. eCollection 2024. Front Neurosci. 2024. PMID: 39664446 Free PMC article.
References
-
- Fleck S., Rumpold-Seitlinger G., Bornemann-Cimenti H. Mechanisms and clinical relevance of the interaction between metamizole and acetylsalicylic acid-a review. Anasthesiol. Intensivmed. 2018;59:180–185.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources